Treasury Secretary Steven Mnuchin has concerns about Facebook's proposed cryptocurrency and its potential illicit use.Marketsread more
Some White House officials expect the Cabinet secretary, who has known the president for years, to depart as soon as this summer.Politicsread more
The Guggenheim CIO says he had been approached by the White House about possibly joining the Federal Reserve.The Fedread more
Epstein is accused of sexually exploiting dozens of underage girls from 2002 through 2005 at his New York and Florida residences. He is a former friend of Presidents Donald...Politicsread more
When you think of Prime Day, you might be thinking about deals on Instant Pots and Amazon Echo devices — not half-off dresses and designer heels. But the market for apparel...Retailread more
Joe Lonsdale says his fellow Palantir co-founder Peter Thiel was "courageous" for speaking out against Alphabet's Google.Technologyread more
Wall Street analysts say it is increasingly possible the Trump administration will try using a stronger weapon in the currency wars than just presidential tweets.Market Insiderread more
Twitter has rebuilt its website from the ground up for the first time ever, here's what it looks like.Technologyread more
Amazon is expanding its empire and Morgan Stanley believes Bezos' ambitious satellite internet plan could become very lucrative.Investing in Spaceread more
Charles Schwab is in talks to buy USAA's brokerage and wealth-management operations for about $2 billion, The Wall Street Journal reported.Wall Streetread more
The talks are expected to be the most contentious in a decade amid "America first" policies from the Trump administration, a tight labor market and thousands of job cuts and...Autosread more
(Adds background, comment from plaintiff lawyer)
March 19 (Reuters) - A U.S. jury on Tuesday found Bayer AG's glyphosate-based weed killer caused a man's non-Hodgkin's lymphoma in a bellwether trial that may help determine the course of hundreds of similar cases.
The finding by the unanimous jury in San Francisco federal court clears the way for that same jury to determine if Bayer unit Monsanto is liable and must pay damages to California resident Edwin Hardeman in a second trial phase.
Bayer in a statement on Tuesday said it was disappointed with the jury's initial decision.
"We are confident the evidence in phase two will show that Monsanto's conduct has been appropriate and the company should not be liable for Mr. Hardeman's cancer," the company said.
The case was only the second of some 11,200 Roundup lawsuits to go to trial in the United States. Another California man was awarded $289 million in August after a state court jury found Roundup caused his cancer, sending Bayer shares plunging at the time. That award was later reduced to $78 million and is on appeal.
Hardeman's case is expected to help determine the range of damages and define settlement options for more than 760 Roundup cases consolidated in the federal court in San Francisco.
Bayer denies allegations that Roundup, or glyphosate, cause cancer. It says decades of studies and regulatory evaluations, primarily of real-world human exposure data, have shown the weed killer to be safe for human use.
After five days of deliberations over scientific evidence presented during the trial, the jury on Tuesday found Roundup, one of the world's most widely-used weed killers, to be a "substantial factor" in causing Hardeman's cancer.
During the first phase, Hardeman's lawyers were not allowed to present evidence allegedly showing the company's efforts to influence scientists, regulators and the public about the safety of its products. They will be able to present that evidence in the second phase.
Hardeman's lawyers, Aimee Wagstaff and Jennifer Moore, said they look forward to presenting that evidence to the jury to hold Monsanto accountable.
"Now we can focus on the evidence that Monsanto has not taken a responsible, objective approach to the safety of Roundup," they said in a statement. (Reporting by Jim Christie in San Francisco; Additional reporting and writing by Tina Bellon in New York Editing by Bill Berkrot)